

Supplementary Material-Table 1: Main Safety and Functional Outcomes of Patients with Propensity Score Matching Model

Outcome	Group	n (%)	PSM	
			OR (95% CI)	P
mRS 0-1 at 3 months	Aspirin	160/182(87.9)	0.77 (0.39-1.50)	0.44
	DAPT	162/181(89.5)	0.90 (0.45-1.79)	0.77
	IV t-PA	161/178(90.4)	ref	
mRS 0-2 at 3 months	Aspirin	168/182(92.3)	0.79 (0.35-1.79)	0.57
	DAPT	169/181(93.4)	0.93 (0.40-2.16)	0.86
	IV t-PA	167/178(93.8)	ref	
Mortality at 3 months	Aspirin	2/182(1.1)	1.00 (0.14-7.18)	1.00
	DAPT	0/181(0.0)	-	0.96
	IV t-PA	2/182(1.1)	ref	

DAPT indicates dual antiplatelet therapy; IV t-PA, recombinant tissue plasminogen activator; OR, odds ratio; CI, confidence intervals; mRS, modified Rankin scale; PSM, propensity score matching.